Bond.az White LogoBond.az Black Logo

PJM board letter positive for power producers

Melius Research sees PJM board letter as positive for independent power producers. Vistra shares up 16%, regulatory changes and market outlook.

Mia Lopez
ByMia Lopez- Senior Editor
|
0

Melius Research views the May 19 PJM Board of Managers letter as a structural positive for independent power producers, according to analyst commentary following discussions with firms including Vistra Corp., Talen Energy Corp., and Constellation Energy Corp.

The letter accelerates the centralized Reliability Backstop Procurement auction to September 2026 from early 2027. Executive teams broadly characterized the letter as very positive, removing approximately six months of regulatory limbo. Analysts remain bullish on Vistra, with revenue climbing 7.4% over the last twelve months.

PJM's Board merged the RBP and Connect and Manage proceedings into a single CIFP process, ending dual-track confusion. Melius says bundling C&M into the Backstop CIFP forces FERC to evaluate the construct as part of a single package, raising the probability of acceptance.

PJM has written to each state governor requesting frameworks to allocate backstop costs to new large load customers. If states do not act, costs default to residential consumers, creating political risk.

The 2027/2028 BRA closed with a shortfall of approximately 6,500 MW. PJM's RBP proposal targeted approximately 14.9 GW of new capacity through 2029. Bond.az data shows Vistra trading near its Fair Value, with analysts setting price targets as high as $320.

More News
Today / 12:35
|
248

BayCom Stock Rating Downgraded After Mgmt Changes

DA Davidson downgrades BayCom stock to Neutral after management changes. Find details on price target, dividend, and new leadership.

0
Today / 12:04
|
789

CoreWeave Stock: AI Infrastructure Demand

Deutsche Bank reaffirms Buy rating on CoreWeave amid AI infrastructure demand. Key financials and market insights.

0
Today / 12:03
|
656

Tenable price target raised to $29

Stephens raised Tenable price target to $29, citing platform focus and AI opportunities. Tenable One adoption and new pricing are key catalysts.

0
Today / 11:03
|
631

Jefferies Raises SentinelOne Price Target to $24

Jefferies raised SentinelOne price target to $24 on margin outlook, maintaining Buy rating. Stock at $18.71, NNARR growth expected. Analyst sees H2 margin expansion.

0
Today / 11:02
|
566

ThinkEquity Initiates Atlas with Buy

ThinkEquity initiates Atlas Technical Consultants with a Buy rating and $15 target. The firm highlights the value of the Brazil critical-minerals option.

0
Today / 11:00
|
941

Reddit Stock Rating Boosted by App Growth

Citizens maintains Market Outperform on Reddit stock with $240 target. App installs surged 129% YoY, driving advertising growth.

0
Today / 10:33
|
492

Wolfe Research Reaffirms Ionis Stock Outperform Rating

Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.

0
Today / 10:31
|
510

BTIG reiterates Uber Buy rating after Delivery Hero bid

BTIG reaffirms Uber Buy rating with $100 target after Delivery Hero bid. Stock seen as undervalued.

0
Today / 10:30
|
550

BTIG Reiterates Neutral on Affirm Stock

BTIG reiterates Neutral on Affirm stock amid credit trends. Analysis of delinquencies, growth prospects, and analyst targets.

0
Today / 10:02
|
707

Mizuho Cuts Intuit Target on TurboTax Weakness

Mizuho cuts Intuit target to $500 on TurboTax weakness; shares fall 20%. Read more on Bond.az.

0
Today / 08:00
|
677

Leerink Reaffirms Eli Lilly Stock Rating on Gene Therapy

Leerink reaffirms Eli Lilly stock rating with Outperform and $1,119 target, citing promising gene therapy data from VERVE-102 trial. Bond.az covers the latest.

0
Today / 06:02
|
602

Goldman Sachs Initiates Hemab Buy

Goldman Sachs initiates Hemab Therapeutics with buy rating. Sutacimig and HMB-002 target rare bleeding disorders.

0
...
PJM board letter positive for power producers | Bond.az